EEA Decision 191/2026 extends six EU feed additive acts to EEA EFTA markets, minus Liechtenstein
The EEA Joint Committee has added six feed additive acts, including a monensin sodium renewal and a Duddingtonia flagrans approval, to Annex I. Market access teams should read it as a lesson in how EU rules reach EEA markets.
What happened
EUR-Lex records that Decision No 191/2026 of the EEA Joint Committee brings six EU feed additive acts into Annex I of the EEA Agreement. Two are named: a renewal of authorisation for monensin sodium and an approval for Duddingtonia flagrans. The decision excludes Liechtenstein.
The record does not name the other four acts. It also does not give the target species, the conditions of use, the date the decision enters into force or the reason for Liechtenstein's exclusion. Those details sit in the legal text and its annexes, and readers should check the Official Journal before drawing conclusions about specific products.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Sources this analysis is based on
- EEA Joint Committee adds six EU feed additive acts to Annex I of EEA Agreement EUR-Lex · Thu 19 Nov 2026
- Health Canada flags Beckman Coulter DxC 500i software fault that may distort chemistry results Health Canada · Wed 18 Nov 2026
- CMS moves Alimetry's Gastric Alimetry test to higher Medicare outpatient payment tier for 2027 Alimetry Inc. · Wed 18 Nov 2026
- ANSM amends French generic groups directory in decision dated 12 November 2026 ANSM · Wed 18 Nov 2026
- Slovenia asks wholesalers to import estradiol 50 microgram patches amid supply disruption JAZMP · Wed 18 Nov 2026
- SÚKL explains why Czech pharmacies may split repeat-prescription dispensing across days SÚKL · Wed 18 Nov 2026
Written by VigiEye's editorial system with AI assistance (model claude-sonnet-5-5) strictly from the official records listed above. It can contain errors: check the sources before acting. Not legal, medical or investment advice.
Tablo power cord overheating alert shows how a simple instruction change becomes a PV control
FDA's early alert on Outset Medical's Tablo cords is a reminder that use-instruction updates depend on reporting, user follow-through and a clear view of what is still unknown.
Lantern Pharma's first TNBC site and Taiwan start meet a CEO exit and a $4.0M raise
Lantern Pharma reported trial milestones for LP-184 and LP-300 in the same release as a CEO resignation and a roughly $4.0M offering, a mix sponsors and CROs should read carefully.
Prescriber fraud plea and a week of enforcement signals: what QA and compliance should take from it
A Missouri physician and spouse admitted drug-prescribing and health care fraud conspiracies; alongside ANSM, BfArM and OIG actions, the day shows how oversight reaches every link in the chain.